Icodextrin reduces @entity2690 resistance in non- XXXX @entity1 undergoing automated @entity298 : results of a randomized controlled trial (STARCH).

@entity1 @entity25508 @entity6 @entity298 @entity2690 @entity740 @entity413
BACKGROUND: @entity2690 resistance is a common risk factor in @entity740 @entity1 contributing to the high cardiovascular burden, even in the absence of @entity6 . @entity413 -based @entity298 ( @entity298 ) solutions are thought to intensify @entity2690 resistance due to the continuous @entity413 absorption from the peritoneal cavity. The aim of our study was to analyse the effect of the substitution of @entity413 for @entity25508 on @entity2690 resistance in @entity6 @entity1 in a multicentric randomized clinical trial. METHODS: This was a multicenter, open-label study with balanced randomization (1:1) and two parallel-groups. Inclusion criteria were non- @entity6 adult @entity1 on automated @entity298 (APD) for at least 3 months on therapy prior to randomization. @entity1 assigned to the intervention group were treated with 2L of icodextrin 7.5%, and the control group with @entity413 2.5% during the long dwell and, at night in the cycler, with a prescription of standard @entity413 -based @entity298 solution only in both groups. The primary end-point was the change in @entity2690 resistance measured by homeostatic model assessment (HOMA) index at 90 days. RESULTS: Sixty @entity1 were included in the intervention (n = 33) or the control (n = 27) groups. There was no difference between groups at baseline. After adjustment for pre-intervention HOMA index levels, the group treated with icodextrin had the lower post-intervention levels at 90 days in both intention to treat [1.49 (95% CI: 1.23-1.74) versus 1.89 (95% CI: 1.62-2.17)], (F = 4.643, P = 0.03, partial   (2) = 0.078); and the treated analysis [1.47 (95% CI: 1.01-1.84) versus 2.18 (95% CI: 1.81-2.55)], (F = 7.488, P = 0.01, partial   (2) = 0.195). CONCLUSIONS: The substitution of @entity413 for icodextrin for the long dwell improved @entity2690 resistance measured by HOMA index in non- @entity6 APD @entity1 .
